Population
Patients undergoing total hip or knee replacement, patients with nonvalvular atrial fibrillation, and…
Design
Review
Authors
Loading...
Supports dabigatran as monitoring-free option in AF and VTE; leaves open need for updated head-to-head data versus current alternatives.
Dabigatran etexilate provides a viable oral anticoagulation option with rapid onset and predictable effects without the need for routine monitoring.
Blommel et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: